Psychopharmacotherapy of Premenstrual Dysphoric Disorder—New Vistas
Nearly forty percent of women with PMDD remain impaired and resistant to first-line agents. This reflects complexity and heterogeneity of etiopathogenesis at the core of PMDD. Some agents, in the pipeline, sound promising that might usher in a new sparkle in the psychopharmacology of PMDD.
Authors
- Ahmed Naguy (ORCID: https://orcid.org/0000-0002-6465-456X)
- Adel Elsheshai
- Bibi Alamiri (ORCID: https://orcid.org/0000-0001-7133-9069)
- Sri Haricharan Thiguti
Institutions
- Kuwait Cancer Control Center (KW)
- Centre for Mental Health (GB)
- Royal College of Psychiatrists (GB)
- Alexandria University (EG)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4447
- Citations
- 1
- Primary Topic
- Menstrual Health and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.88